NIHR | Manchester Biomedical Research Centre
Our Research: Musculoskeletal

Childhood arthritis

Juvenile Idiopathic Arthritis can have a lifelong impact, how can we improve outcomes for young people?

Juvenile Idiopathic Arthritis has a lifelong impact, with 60% of patients reporting reduced function into adulthood. This is added to the impact it can have on parents, siblings and a young person’s other relationships.

We are working to develop new treatments and disease management strategies to improve outcomes for patients.

Through our research we are:

  • Working with young people to test whether the new approaches we have developed to assess and communicate about pain, utilising apps and questionnaires, help to reduce the impact of pain and improve outcomes
  • Developing online solutions to assist arthritis self-management and utilise our informatics strength to develop longitudinal data gathering methods to refine interventions for those transitioning into adult services
  • Piloting the ultra-low dosage of IL2 treatment in a subset of targeted patients, who we believe will respond to treatment based on their genetic profile
  • Through the CLUSTER Consortium, ringing together knowledge from internationally-recognised leaders in JLA, bioinformatics and industry, to develop biomarker tests and predict disease outcomes for JLA patients.